Cytomx Therapeutics, INC 10-Q quarterly reports

CytomX Therapeutics reported a significant revenue decline and net loss for the third quarter of 2025, but strengthened its financial position with a recent capital raise and advanced key clinical programs.

CytomX Therapeutics reports a significant increase in cash and investments, driven by a recent public offering, while advancing its lead oncology programs CX-2051 and CX-801 despite some collaboration terminations.

CytomX Therapeutics reports increased revenue in Q1 2025 driven by collaboration agreements, while also announcing pipeline prioritization and restructuring efforts to extend cash runway.

CytomX Therapeutics reports a profitable third quarter, driven by increased collaboration revenue and progress in clinical development programs.

CytomX Therapeutics reports a net loss of $6.5 million for Q2 2024, while highlighting advancements in its clinical programs and collaborations.

CytomX Therapeutics reports a strong first quarter of 2024, marked by increased revenue from collaborations and advancements in its clinical programs.